Multidrug Resistant Bacteria Global Market Report 2024

Description

“Multidrug Resistant Bacteria Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multidrug resistant bacteria market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for multidrug resistant bacteria? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The multidrug resistant bacteria market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Disease: Urinary Tract Infection; Intra-Abdominal Infections; Blood Stream Infections; Clostridium Difficile Infections; Acute Bacterial Skin And Skin Structure Infections; Hospital Acquired Bacterial Pneumonia; Acquired Bacterial Pneumonia; Other Diseases
2) By Drug Class: Oxazolidinones; Lipoglycopeptides; Tetracyclines; Cephalosporins; Combination Therapies; Other Drug Classes
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson And Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Multidrug-resistant bacteria are strains of bacteria that have developed resistance to multiple classes of antibiotics, rendering them no longer susceptible to the effects of several different antibiotics that are typically effective in treating bacterial infections. These resilient bacteria are often found in hospital and medical care settings, where antibiotics are sometimes overused or used unnecessarily.

Various diseases are caused by multidrug-resistant bacteria, including urinary tract infections, intra-abdominal infections, bloodstream infections, Clostridium difficile infections, acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia, among others. Urinary tract infections, for example, can affect different parts of the urinary system, such as the kidneys, bladder, and ureters. The treatment of these diseases involves the use of various drugs, including oxyazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and more, administered through oral, parenteral, and other routes. These treatments are provided to patients in various healthcare settings, including hospitals, specialty clinics, homecare, and others.

The multidrug-resistant bacteria market research report is one of a series of new reports from The Business Research Company that provides multidrug-resistant bacteria market statistics, including multidrug-resistant bacteria industry global market size, regional shares, competitors with a multidrug-resistant bacteria market share, detailed multidrug-resistant bacteria market segments, market trends and opportunities and any further data you may need to thrive in the multidrug-resistant bacteria industry. This multidrug-resistant bacteria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The multidrug resistant bacteria market size has grown strongly in recent years. It will grow from $11.86 billion in 2023 to $12.61 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antibiotic resistance crisis, advancements in drug discovery, regulatory incentives, public health initiatives.

The multidrug resistant bacteria market size is expected to see strong growth in the next few years. It will grow to $16.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to antibiotic stewardship programs, global spread of resistance, phage therapy and alternative treatments, public and private investment. Major trends in the forecast period include precision medicine for infectious diseases, combination therapies, continuous surveillance and monitoring, global collaboration.

The rising prevalence of infectious diseases is expected to drive the growth of the multidrug-resistant bacteria market in the future. Infectious diseases encompass illnesses caused by harmful microorganisms like bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are closely linked to infectious diseases because they can lead to infections that are challenging to treat with conventional antibiotics. These bacteria have developed resistance to multiple antibiotics, reducing their susceptibility to commonly used medications for bacterial infections. For instance, data from the Australian Institute of Health and Welfare (AIHW), an Australian government agency, revealed that the number of notifiable infectious diseases in Australia increased from 289,013 in 2020 to 701,820 in 2021. Therefore, the growing prevalence of infectious diseases will be a driving force behind the multidrug-resistant bacteria market.

The complexity of infections is impeding the growth of the multidrug-resistant bacteria market during the forecast period. Infections caused by multidrug-resistant (MDR) bacteria can be more severe and challenging to treat compared to infections caused by susceptible bacteria. This complexity can result in extended hospital stays, increased healthcare costs, and poorer patient outcomes. For instance, a report published in the Lancet, a UK-based peer-reviewed journal, in February 2022 suggested that by 2050, antimicrobial resistance (AMR) might be responsible for up to 10 million annual deaths. Therefore, the impact of infection complexity is presenting a hindrance to the growth of the multidrug-resistant bacteria market.

Major companies operating in the multidrug-resistant bacteria market are placing a strong emphasis on the development of innovative drugs and securing approvals to address the needs of a new segment of consumers. The approval of drugs designed to combat multidrug-resistant bacteria is crucial in the ongoing fight against antibiotic resistance. For example, in May 2023, Entasis Therapeutics Inc., a US-based biotech company, achieved approval from the Food and Drug Administration (FDA) for Xacduor, a combination antibiotic formulated to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) caused by acinetobacter baumannii, a particularly challenging pathogen to treat. Xacduor consists of a combination of ceftolozane and tedizolid phosphate. Ceftolozane is a cephalosporin antibiotic, while tedizolid phosphate belongs to the oxazolidinone class of antibiotics. This approval provides a new treatment option for patients infected with Acinetobacter baumannii who have not responded to other therapies. It can be administered via injection and combines the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam, reducing acinetobacter resistance and enabling the antibiotic to effectively combat the infection.

In July 2022, Innoviva Inc., a US-based pharmaceutical company, acquired Entasis Therapeutics Inc. for an undisclosed amount. This strategic acquisition expands Innoviva's portfolio, encompassing potential first- and best-in-class medications for the treatment of multidrug-resistant gram-negative bacteria, including the lead asset SUL-DUR. Entasis Therapeutics Inc. is a US-based biotech company specializing in the development of antibacterial therapeutics aimed at addressing serious infections caused by multidrug-resistant bacteria.

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

North America was the largest region in the multidrug-resistant bacteria market in 2023. The regions covered in multidrug-resistant bacteria report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multidrug-resistant bacteria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multidrug-resistant bacteria market consists of revenues earned by entities by providing services such as infection diagnosis and combination therapy, surgery and antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The multidrug-resistant bacteria market also consists of sales of colistin, polymyxins, aminoglycosides, antibiotic synergy kits, monoclonal antibodies and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12390

1. Executive Summary

2. Multidrug Resistant Bacteria Market Characteristics

3. Multidrug Resistant Bacteria Market Trends And Strategies

4. Multidrug Resistant Bacteria Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Multidrug Resistant Bacteria Market Size and Growth

5.1. Global Multidrug Resistant Bacteria Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Multidrug Resistant Bacteria Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Multidrug Resistant Bacteria Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Multidrug Resistant Bacteria Market Segmentation

6.1. Global Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Urinary Tract Infection
Intra-Abdominal Infections
Blood Stream Infections
Clostridium Difficile Infections
Acute Bacterial Skin And Skin Structure Infections
Hospital Acquired Bacterial Pneumonia
Acquired Bacterial Pneumonia
Other Diseases
6.2. Global Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oxazolidinones
Lipoglycopeptides
Tetracyclines
Cephalosporins
Combination Therapies
Other Drug Classes
6.3. Global Multidrug Resistant Bacteria Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Parenteral
Other Routes Of Administration
6.4. Global Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users

7. Multidrug Resistant Bacteria Market Regional And Country Analysis

7.1. Global Multidrug Resistant Bacteria Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Multidrug Resistant Bacteria Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Multidrug Resistant Bacteria Market

8.1. Asia-Pacific Multidrug Resistant Bacteria Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Multidrug Resistant Bacteria Market

9.1. China Multidrug Resistant Bacteria Market Overview
9.2. China Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Multidrug Resistant Bacteria Market

10.1. India Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Multidrug Resistant Bacteria Market

11.1. Japan Multidrug Resistant Bacteria Market Overview
11.2. Japan Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Multidrug Resistant Bacteria Market

12.1. Australia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Multidrug Resistant Bacteria Market

13.1. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Multidrug Resistant Bacteria Market

14.1. South Korea Multidrug Resistant Bacteria Market Overview
14.2. South Korea Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Multidrug Resistant Bacteria Market

15.1. Western Europe Multidrug Resistant Bacteria Market Overview
15.2. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Multidrug Resistant Bacteria Market

16.1. UK Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Multidrug Resistant Bacteria Market

17.1. Germany Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Multidrug Resistant Bacteria Market

18.1. France Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Multidrug Resistant Bacteria Market

19.1. Italy Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Multidrug Resistant Bacteria Market

20.1. Spain Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Multidrug Resistant Bacteria Market

21.1. Eastern Europe Multidrug Resistant Bacteria Market Overview
21.2. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Multidrug Resistant Bacteria Market

22.1. Russia Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Multidrug Resistant Bacteria Market

23.1. North America Multidrug Resistant Bacteria Market Overview
23.2. North America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Multidrug Resistant Bacteria Market

24.1. USA Multidrug Resistant Bacteria Market Overview
24.2. USA Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Multidrug Resistant Bacteria Market

25.1. Canada Multidrug Resistant Bacteria Market Overview
25.2. Canada Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Multidrug Resistant Bacteria Market

26.1. South America Multidrug Resistant Bacteria Market Overview
26.2. South America Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Multidrug Resistant Bacteria Market

27.1. Brazil Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Multidrug Resistant Bacteria Market

28.1. Middle East Multidrug Resistant Bacteria Market Overview
28.2. Middle East Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Multidrug Resistant Bacteria Market

29.1. Africa Multidrug Resistant Bacteria Market Overview
29.2. Africa Multidrug Resistant Bacteria Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Multidrug Resistant Bacteria Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Multidrug Resistant Bacteria Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Multidrug Resistant Bacteria Market Competitive Landscape And Company Profiles

30.1. Multidrug Resistant Bacteria Market Competitive Landscape
30.2. Multidrug Resistant Bacteria Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson And Johnson Private Limited
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck And Co. Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Bayer AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Multidrug Resistant Bacteria Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca plc
31.5. GlaxoSmithKline plc
31.6. Eli Lilly and Company
31.7. Boehringer Ingelheim International GmbH
31.8. Gilead Sciences Inc.
31.9. Teva Pharmaceutical Industries Ltd.
31.10. Mylan N.V.
31.11. Dr. Reddy's Laboratories Ltd.
31.12. Lupin Pharmaceuticals Inc.
31.13. BioMarin Pharmaceuticals Inc.
31.14. Zydus Lifesciences Limited
31.15. Glenmark Pharmaceuticals Ltd.

32. Global Multidrug Resistant Bacteria Market Competitive Benchmarking

33. Global Multidrug Resistant Bacteria Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Multidrug Resistant Bacteria Market

35. Multidrug Resistant Bacteria Market Future Outlook and Potential Analysis

35.1 Multidrug Resistant Bacteria Market In 2028 - Countries Offering Most New Opportunities
35.2 Multidrug Resistant Bacteria Market In 2028 - Segments Offering Most New Opportunities
35.3 Multidrug Resistant Bacteria Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer